—Researchers provide the most comprehensive genetic synopsis of primary biliary cholangitis to date, identifying 44 risk-associated variants with strong evidence for novel genome-wide significant loci ...

"Future guidelines panels could review these results and consider recommending the inclusion of immunotherapy with chemotherapy for the first-line treatment of advanced biliary tract cancer in the ...

Dear Dr. Roach: I am an 85-year-old female who has had primary biliary cirrhosis of the liver for many years. I have been on 300 mg of ursodiol taken three times a day for all those years, with no ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Epidemiologically, PBC is more commonly ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Patients with cholestatic liver disease such as primary biliary cholangitis (PBC) can experience significant impairment of bile flow and may develop neurological symptoms including fatigue and ...

21. Data from phase III randomized trials for budesonide (in non-cirrhotic patients) and bezafibrate, both in combination with UDCA, are not yet published; EASL suggests that currently a ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE ...

– Recommendation Based on the RESPONSE Study Which Demonstrated ALP Normalization in 25% of Participants at 12 Months and Statistically Significant Reduction of Pruritus Versus Placebo – – If Approved ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi ® (seladelpar) ...

(RTTNews) - Gilead Sciences Inc. (GILD) announced that the U.S. Food and Drug Administration has granted accelerated approval for Livdelzi (seladelpar) to treat primary biliary cholangitis or PBC.

The accelerated approval was based primarily on data from the pivotal placebo-controlled Phase 3 RESPONSE study. In the study, 62% of participants taking Livdelzi achieved the primary endpoint of ...